Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 316 participants.
Also called NCT04239950
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 316 participants
- Registry
-
NCT04239950
-
- Other papers using this trial's data
- Efficacy and safety of highly purified ethyl icosapentate soft capsules (MND-21) for the treatment of severe hypertriglyceridemia: A 12-week, multi-center, placebo-controlled, randomized, double-blind, phase III clinical trial in China
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04239950. Randomized; quadruple masking; primary purpose treatment. Start 2020-05-09 (actual); primary completion 2023-07-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Ethyl Icosapentate
- Lead sponsor
- Mochida Pharmaceutical Company, Ltd.
- Collaborator
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Record details
- Record id
cardio:ct-nct04239950- Content hash
50030282e3e60ad4c994f5a8721026c2e50a275263f7657081c25d681b9638fc